Iterion Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapeutics. It provides Tegavivint, a selective inhibitor of the Wnt/β-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint focuses on desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types.